|
Status |
Public on Mar 26, 2020 |
Title |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer |
Organisms |
Homo sapiens; synthetic construct |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing Other
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
Web link |
https://pubmed.ncbi.nlm.nih.gov/32220301/
|
|
|
Citation(s) |
32220301 |
|
Submission date |
Feb 22, 2019 |
Last update date |
Jun 25, 2020 |
Contact name |
Ping Mu |
E-mail(s) |
muping817@gmail.com
|
Organization name |
UT Southwestern Medical Center
|
Department |
Human Oncology and Pathogenesis
|
Lab |
Mu Lab
|
Street address |
6000 Harry Hines Blvd., NA6.308A
|
City |
Dallas |
State/province |
TX |
ZIP/Postal code |
76092 |
Country |
USA |
|
|
Platforms (3) |
GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
GPL19604 |
Illumina HiSeq 2500 (synthetic construct) |
GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
Samples (453)
|
|
This SuperSeries is composed of the following SubSeries: |
GSE126917 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [RNA-seq] |
GSE127241 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [ATAC-seq] |
GSE127957 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [shRNA screen] |
|
Relations |
BioProject |
PRJNA523724 |